CRISPR-Cas9-based target validation for p53-reactivating model compounds

Inactivation of the p53 tumor suppressor by Mdm2 is one of the most frequent events in cancer, so compounds targeting the p53-Mdm2 interaction are promising for cancer therapy. Mechanisms conferring resistance to p53-reactivating compounds are largely unknown. Here we show using CRISPR-Cas9–based ta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Chem Biol
Main Authors: Wanzel, Michael, Vischedyk, Jonas B, Gittler, Miriam P, Gremke, Niklas, Seiz, Julia R, Hefter, Mirjam, Noack, Magdalena, Savai, Rajkumar, Mernberger, Marco, Charles, Joël P, Schneikert, Jean, Bretz, Anne Catherine, Nist, Andrea, Stiewe, Thorsten
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910870/
https://ncbi.nlm.nih.gov/pubmed/26595461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nchembio.1965
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados